Kyntra Bio Inc. released a corporate presentation outlining its oncology and hematology pipeline. The company highlighted FG-3246, a CD46-targeting antibody-drug conjugate, and FG-3180, a PET imaging agent being evaluated as a potential patient selection biomarker in metastatic castration-resistant prostate cancer. Kyntra Bio said a Phase 2 monotherapy trial in post-ARPI, pre-chemotherapy mCRPC is enrolling, with interim data expected in the second half of 2026. The presentation also described roxadustat as a Phase 3-ready U.S. development opportunity in anemia due to low-risk myelodysplastic syndromes, noting FDA alignment on key Phase 3 trial design elements and Orphan Drug Designation granted in December 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.